After reviewing the science and consulting top experts at NIH and fda, HHS has determined that MRNA technology poses more risk and benefits for these respiratory viruses. That's why, after extensive review, BARDA has begun the process of terminating these 22 contracts, totaling just under $500 million. to replace the troubled MRNA programs. We're prioritizing the development of safer, broader vaccine strategies, like whole virus vaccines and novel platforms that don't collapse when viruses mutate. (01:46–01:54)
CLAIM
Asserts that BARDA is terminating contracts worth just under $500 million.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
